Alzheimer's Archives

News and Trends 17 Jul 2023

Hope for Alzheimer’s patients after Lilly drug results

Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]

July 17, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 13 Jul 2023

Partnership to progress neurodegenerative disorder treatments

IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]

July 13, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

FDA approves Alzheimer’s treatment

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […]

July 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 23 Jun 2023

SandboxAQ launches new division to boost drug development

After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […]

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2023

Alchemab Therapeutics unveils Alzheimer’s candidate

Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France. ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein thought to have a key role in Alzheimer’s disease. […]

June 22, 2023 - 3 minutesmins - By Jim Cornall

induced pluripotent stem cells ipsc Alzheimer's

News and Trends 13 Jun 2023

‘Clinical trial in a dish’ for Alzheimer’s disease

Axol Bioscience Ltd., a pluripotent stem cell technology provider for drug discovery, has signed an agreement with StrataStem to access and commercialize its collection of Alzheimer’s disease (AD) patient samples. Harnessing its stem cell knowledge, Axol will reprogram these patient samples into induced pluripotent stem cells (iPSCs) that can then be differentiated into a wide […]

June 13, 2023 - 3 minutesmins - By Jim Cornall

In Depth 13 Jun 2023

Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines

By Dr. Andrea Pfeifer, CEO of AC Immune SA The clinical success we’ve recently seen with two monoclonal antibodies that target the protein amyloid beta (Abeta) has provided hope for patients, a significant boost to the sector but also a strong validation of the “amyloid hypothesis”: removing Abeta plaques is a valid therapeutic strategy for […]

June 13, 2023 - 7 minutesmins - By External Contributor

AI artificial intelligence dementia alzheimer's

News and Trends 13 Jun 2023

How AI can advance research and treatment of CNS disorders

By Xiao Xu, senior research fellow, Cerevance The combination of large-scale biological datasets and developments in artificial intelligence (AI) has revolutionized our understanding and treatment of central nervous system (CNS) disorders. By leveraging AI’s computational power, researchers have been able to interrogate diverse datasets to provide insights into disease mechanisms, discover novel therapeutic compounds, detect […]

June 13, 2023 - 3 minutesmins - By External Contributor

Best in Biotech 12 Jun 2023

Six advancements in Alzheimer’s research over the past year

The most common cause of dementia, Alzheimer’s disease, is a brain disorder that is characterized by cognitive decline which often manifests itself through memory loss, feelings of disorientation and difficulty making decisions. Alzheimer’s occurs when there is an excessive accumulation of proteins in the brain, a hallmark feature of the disease. These proteins, namely, amyloid […]

June 12, 2023 - 12 minutesmins - By Roohi Mariam Peter

News and Trends 30 May 2023

New study reveals Alzheimer’s inflammation protection

A possible explanation has been found in a study for why apoE4, the most significant genetic risk factor associated with Alzheimer’s disease, fails to protect the brain from inflammation.Alzheimer’s disease is characterized by the accumulation of plaques of the amyloid-β protein, chronic inflammation and impaired neuronal function in the brain. The most significant genetic risk […]

May 30, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 25 May 2023

Researchers discover genetic variation offers Alzheimer’s disease clues

A new study conducted by researchers at the University of Eastern Finland discovered that the APP A673T genetic variant, which protects against Alzheimer’s disease (AD), alters levels of several proteins and peptides linked to amyloid-beta metabolism in human biofluids and cell culture models, including amyloid beta itself. These new data support the idea that even […]

May 25, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 22 May 2023

Cancer implications as new molecule can kill ‘zombie’ cells

Over time, the body’s cells stop working properly and begin to accumulate, which eventually leads to tissues aging. Researchers at the UOC (Universitat Oberta de Catalunya) in Spain, in collaboration with the University of Leicester in the U.K. have discovered a new molecule that is able to destroy these old cells without affecting healthy ones. […]

May 22, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us